Atorvastatin Calcium Hydrate/Glimepiride

阿托伐他汀钙/格列美脲

Report date: 2022/07/04 19:38:02

Base Information

Drug NameAtorvastatin Calcium Hydrate/Glimepiride

Drug Alias NameGlimepiride/Atorvastatin Calcium Hydrate格列美脲/阿托伐他汀钙Atorvastatin Calcium Hydrate and GlimepirideGlimepiride/atorvastatinAtorvastatin/Glimepiride

ClassificationSmall molecules

Mechanisms of ActionHMG-CoA reductase inhibitorsKATP channels blockersSulfonylurea receptor modulators

TargetsSulfonylurea receptorKATP channelsHMG-CoA reductase

Therapy Area/IndicationsDiabetes Mellitus, Type 2

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryThailandPhilippinesMexico +[6]

CombinationsYes Glimepiride Atorvastatin Calcium Hydrate

Global Highest StatusPending (Phase 3 Clinical)

Highest Status in ChinaN/A

Originator CompaniesGlaxosmithkline Plc

China Registration ClassN/A

Develop Information

Active CompaniesN/A

Inactive CompaniesGlaxosmithkline Plc

Active IndicationsN/A

Inactive IndicationsDiabetes Mellitus, Type 2

Other Information

ATC CodeN/A